Clinical evaluation of traditional Chinese medicine on moderate active ulcerative colitis: a multi-center, randomized, double-blind, controlled trial

Dongfang Hospital of Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Diagnosis is in line with the active period of ulcerative colitis;
•2. According to the improved Mayo score standard, the condition is moderate (score 6-10 points);
•3. Differentiation of TCM syndrome is heat-dampness and stasis blocked accompanied with defeciency of spleen yang;
•4. 18 to 65 years old;
•5. Those who participate in this clinical study voluntarily, and have signed informed consent already.

•1. Patients during remission period, mild and severe active periods;
•2. Pregnancy, lactation, or birth planning recent ;
•3. Severe allergy tendency and those who allergies to the known ingredients of mesalazine or Qingchang Wenzhong Formula;
•4. Combined with severe cardiovascular and cerebrovascular diseases (chronic heart failure, cardiac function is level III or above according to New York grading standard, severe arrhythmia, severe stroke sequelae). Liver, kidney and hematopoietic system has serious primary diseases, including blood ALT, AST and Cr over the normal upper limit;
•5. Ulcerative colitis companied with serious complications, such as local stenosis, intestinal obstruction, intestinal perforation, multiple polyps in the intestine, toxic megacolon, rectal cancer, etc.
•6. Patients with mental disorders and mental disorders;
•7. Patients who have participated in other meidical clinical studies in the past 3 months;
•8. In addition to mesalazine, patients are receiving other treatments for ulcerative colitis;
•9. Seriously conditions which need to be carried on urgent treatments.

发起方

Dongfang Hospital of Beijing University of Chinese Medicine